Faculty, Staff and Student Publications

Publication Date

4-12-2022

Journal

Nature Communications

Abstract

Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitumor immunity. Understanding of the mechanisms of arthritis-irAE is critical to overcome this challenge, but the pathophysiology remains unknown. Here, we comprehensively analyze peripheral blood and/or synovial fluid samples from 20 patients with arthritis-irAE, and unmask a prominent Th1-CD8

Keywords

Arthritis, CD8-Positive T-Lymphocytes, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms, Tumour immunology, Autoimmunity, Tumour immunology

Comments

This article has been corrected. See Nat Commun. 2024 Jul 4;15:5621.

DOI

10.1038/s41467-022-29539-3

PMID

35413951

PMCID

PMC9005525

PubMedCentral® Posted Date

4-12-2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.